




### 3.1.3 Neuroprotective Strategies in Neurodegenerative Diseases Group

Publications: 10

Impact Factor: 88.483

Q1: 6



#### Research Activity

##### Publications

- Casas AI, Nogales C, Mucke HAM, Petrain A, Cuadrado A, Rojo AI, Ghezzi P, Jaquet V, Augsburger F, Dufasne F, Soubhye J, Deshwal S, Di Sante M, Kaludercic N, Di Lisa F, Schmidt HHHW. On the Clinical Pharmacology of Reactive Oxygen Species. *Pharmacol Rev.* 2020; 72(4): 801-28. Review. IF: 25.468; D1
- Robledinos-Antón N, Escoll M, Guan KL, Cuadrado A. TAZ Represses the Neuronal Commitment of Neural Stem Cells. *Cells.* 2020; 9(10): 2230. Article. IF: 6.6; Q2
- Escoll M, Lastra D, Robledinos-Antón N, Wandosell F, Antón IM, Cuadrado A. WIP modulates oxidative stress through NRF2/KEAP1 in glioblastoma cells. *Antioxidants.* 2020; 9(9): 773. Article. IF: 6.312; D1
- Cuadrado A, Pajares M, Benito C, Jiménez-Villegas J, Escoll M, Fernández-Gines R, Yagüe AJG, Lastra D, Manda G, Rojo AI, Dinkova-Kostova AT. Can activation of NRF2 be a strategy COVID-19? *Trends Pharmacol Sci.* 2020; 41(9): 598-610. Review. IF: 14.819; D1
- Cuadrado A, Perello C, Cabezas J, Llerena S, Llop E, Escudero MD, Hernández-Conde M, Puchades L, Redondo C, Fortea JI, de Miguel AG, Serra MA, Calleja JL, Crespo J. Update on epidemiology of hepatitis B in a low-endemic European country: There is still much to do. *J Viral Hepatitis.* 2020; 27(11): 1261-5. Article. IF: 3.728; Q2
- Pajares M, Rojo AI, Manda G, Bosca L, Cuadrado A. Inflammation in Parkinson's disease: Mechanisms and therapeutic implications. *Cells.* 2020; 9(7): 1687. Review. IF: 6.6; Q2
- Martín-Hurtado A, Lastres-Becker I, Cuadrado A, García-Gonzalo FR. NRF2 and primary cilia: An emerging partnership. *Antioxidants.* 2020; 9(6): 475. Review. IF: 6.312; D1
- Herrera-Arozamena C, Estrada-Valencia M, Pérez C, Lagartera L, Morales-García JA, Pérez-Castillo A, Franco-González JF, Michaiska P, Duarte P, Leon R, López MG, Mills A, Gago F, García-Yagüe AJ, Fernández-Ginés R, Cuadrado A, Rodríguez-Franco MI. Tuning melatonin receptor subtype selectivity in oxadiazolone-based analogues: Discovery of QR2 ligands and NRF2 activators with neurogenic properties. *Eur J Med Chem.* 2020; 190: 112090. Article. IF: 6.514; D1
- Michalska P, Buendía I, Duarte P, Fernández Mendivil C, Negro P, Cuadrado A, López MG, Leon R. Melatonin-sulforaphane hybrid ITH12674 attenuates glial response in vivo by blocking LPS binding to MD2 and receptor oligomerization. *Pharmacol Res.* 2020; 152: 104597. Article. IF: 7.658; D1
- Shi L, Winchester LM, Liu BY, Killick R, Ribe EM, Westwood S, Baird AL, Buckley NJ, Hong SJ, Dobricic V, Kilpert F, Franke A, Kiddle S, Sattler M, Dobson R, Cuadrado A, Hye A, Ashton NJ, Morgan AR, Bos I, Vos SJB, ten Kate M, Scheltens P, Vandenberghe R, Gabel S, Meersmans K, Engelborghs S, De Roeck EE, Sleegers K, Frisoni GB, Blin O, Richardson JC, Boret R, Molinuevo JL, Rami L, Wallin A, Kettunen P, Tsolaki M, Verhey F, Lleo A, Alcolea D, Popp J, Peyratout G, Martinez-Lage P, Tainta M, Johannsen P, Teunissen CE, Freund-Levi Y, Frolich L, Legido-Quigley C, Barkhof F, Blennow K, Rasmussen KL, Nordestgaard BG, Frikke-Schmidt R, Nielsen SF, Soininen H, Vellas B, Kloszewska I, Mecocci P, Zetterberg H, Morgan BP, Streffer J, Visser PJ, Bertram



## 3.1 Neuroscience Area

L, Nevado-Holgado AJ, Lovestone S. Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer's Disease Pathology. *J Alzheimers Dis.* 2020; 77(3): 1353-68. Article. IF: 4.472; Q2

### Research projects

**Martínez Valverde A.** Mecanismos moleculares y comunicación intertisular en la resistencia a la insulina [B2017/BMD-3684 MOIR2-CM]. CAM. 2018-2020.

**Management centre:** CISC

**Cuadrado A; Lastres-Becker I.** Papel de NRF2 en la función y el destino del cerebro con Alzheimer [SAF2016-76520-R]. Ministerio de Ciencia e Innovación. 2017-2020.

**Management centre:** UAM

### Cibers and Retics

**Cuadrado Pastor A.** Networked Biomedical Research Center for Neurodegenerative Diseases. (CIBERned). ISCIII. (31/12/2020).

**Management centre:** UAM

### Patents and trademarks

**Cuadrado Pastor A, Innamorato NG,** inventors; CSIC, UAM. Use of sulforaphane as supplementary therapy for early-stage neurodegenerative disease. P201231693; 2012 November 06.

**León Martínez R, Egea Maíquez J, Buendía Abaitua I, Parada Pérez E, Navarro González de Mesa E,** inventors; Fundación para la Investigación Biomédica del Hospital Universitario de La Princesa, UAM, CSIC, DNS NEUROSCIENCE S.A., assignees. Use of 3-[2-isothiocyanatoethyl]-5-methoxy-1H-indole for the treatment of neurodegenerative diseases. P201300667; 2013 July 17.

**León Martínez R, Buendía Abaitua I, Navarro González de Mesa E, Michalska P, Gameiro Ros I, López Vivo A, Egea Maíquez J, García López M, García García A,** inventors; Fundación para la Investigación Biomédica del Hospital Universitario de La Princesa, UAM, DNS NEUROSCIENCE S.A., assignees. Com-

pounds derived from 3-alkylamine-1H-indolyl acrylate and its use for the treatment of neurodegenerative diseases. P201400810, PCT/ES2015/000139, CA2964309; 2014 October 15.